Search
Gastric intrinsic factor
go.drugbank.com/drugs/DB09349ApprovedIntrinsic factor (IF), also known as gastric intrinsic factor (GIF), is a glycoprotein produced by the parietal cells of the stomach that is necessary for the absorption of vitamin B12 (cobalamin) later
Tabelecleucel
go.drugbank.com/drugs/DB17072ApprovedInvestigationalTabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). … When given to a patient with EBV-associated post-transplant lymphoproliferative disorder (PTLD) following solid organ transplantation (SOT) or hematopoietic cell transplant, T-cells attack the patient's
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of [tetrabenazine], most treatments were ineffective. … The reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910]
Gold
go.drugbank.com/drugs/DB14154InvestigationalA yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. … Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Carbocisteine
go.drugbank.com/drugs/DB04339ApprovedInvestigationalIndividuals with COPD have a greater risk of pulmonary infection due to the growth and accumulation of viruses and bacteria in thick bronchial mucus. … Carbocisteine is a mucolytic drug that alleviates respiratory symptoms and infections by reducing the viscosity of mucus, allowing it to be expelled.
13-deoxydoxorubicin
go.drugbank.com/drugs/DB05706InvestigationalGPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414] … episodes in patients with hemophilia A.
Human C1-esterase inhibitor
go.drugbank.com/drugs/DB06404ApprovedInvestigational[L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction
Products: CİNRYZE 500 IU/5 ML IV ENJEKSİYONLUK ÇÖZELTİ İÇİN LİYOFİLİZE TOZ VE ÇÖZÜCÜ, 2 ADETLigelizumab
go.drugbank.com/drugs/DB11856Investigationala greater affinity for free serum IgE and an altered sensitivity to IgE conformation. … Similar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer
19-norandrostenedione
go.drugbank.com/drugs/DB01434ExperimentalIllicitAfter 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency. … In the body 19-norandrostenedione is rapidly metabolized into [nandrolone], also known as nortestosterone.